TITLE

Can clinical factors be determinants of bone metastases in non-small cell lung cancer?

AUTHOR(S)
Ursavas, Ahmet; Karadag, Mehmet; Uzaslan, Esra; Rodoplu, Erkan; Demirdögen, Ezgi; Burgazlioglu, Basak; Gozu, R. Oktay
PUB. DATE
January 2007
SOURCE
Annals of Thoracic Medicine;Jan-Mar2007, Vol. 2 Issue 1, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: The aim of this study was to investigate the correlations among symptoms, laboratory findings of bone metastasis and whole body bone scanning (WBBS) and the frequency of occurrence of bone metastases MATERIALS AND METHODS: Hundred and six patients who were diagnosed with non-small cell lung cancer (NSCLC) between June 2001 and September 2005 were investigated retrospectively. Bone pain, detection of bone tenderness on physical examination, hypercalcemia and increased serum alkaline phosphatase were accepted clinical factors of bone metastases. Presence of multiple asymmetric lesions in WBBS was also accepted as bone metastases. Subjects whose clinical factors and WBBS indicated doubtful bone metastases were evaluated with magnetic resonance and/or biopsy. RESULTS: Occurrence of bone metastases was 31.1% among all patients. Bone metastases were determined in 21 (52.5%) of 40 patients who had at least one clinical factor. Asymptomatic bone metastases without any clinical factors were established in 11.3% of all NSCLC patients and 15.3% of 26 operable patients. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the clinical factors of bone metastases were 63.6, 73.9, 52.5, 81.8 and 70.7% respectively. There was no significant relationship between histologic type and bone metastases. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of WBBS in detection of bone metastases were 96.9, 86.3, 76.2, 98.4, 89.6% respectively. CONCLUSION: Sensitivity and specificity of the clinical factors of bone metastases are quite low. Routine WBBS prevented futile thoracotomies. Therefore, routine WBBS should be performed in all NSCLC patients, even in the absence of bone-specific clinical factors.
ACCESSION #
23887133

 

Related Articles

  • Skeletal Metastasis of Unknown Primary Origin at the Initial Visit: A Retrospective Analysis of 286 Cases. Takagi, Tatsuya; Katagiri, Hirohisa; Kim, Yongji; Suehara, Yoshiyuki; Kubota, Daisuke; Akaike, Keisuke; Ishii, Midori; Mukaihara, Kenta; Okubo, Taketo; Murata, Hideki; Takahashi, Mitsuru; Kaneko, Kazuo; Saito, Tsuyoshi // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Background: Skeletal metastasis is a common metastatic event for several carcinomas, and the treatment for skeletal metastasis of unknown primary (SMUP) are a critical issue in cancer therapy. Making a diagnosis of the primary site is the most crucial step in the treatment of SMUP; however, the...

  • Symptom clusters in cancer patients with bone metastases. Grace Fan; Stephanie Hadi; Linda Filipczak // Supportive Care in Cancer;Sep2007, Vol. 15 Issue 9, p1035 

    Abstract Purpose  The purpose of this study is to explore whether bone pain “clusters” with other symptoms in patients with bone metastases. Materials and methods  Patients with bone metastases referred to a palliative radiotherapy clinic were asked to rate their...

  • Surgical treatment of bone metastases in patients with lung cancer. Utzschneider, Sandra; Wicherek, Ewa; Weber, Patrick; Schmidt, Gerwin; Jansson, Volkmar; Dürr, Hans Roland // International Orthopaedics;May2011, Vol. 35 Issue 5, p731 

    Lung cancer is the leading cause of cancer mortality. Bone metastases are a common complication in lung cancer. The therapeutic approach and the type of surgical treatment of these lesions have not been clearly defined. Outcome and prognosis of patients with bony metastases and a variety of...

  • Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response. Yamashita, Yoshiko; Aoki, Takatoshi; Hanagiri, Takeshi; Yoshii, Chiharu; Mukae, Hiroshi; Uramoto, Hidetaka; Korogi, Yukunori // Skeletal Radiology;Apr2012, Vol. 41 Issue 4, p409 

    Objective: To assess the frequency of osteosclerotic changes on CT that appeared after treatment with gefitinib in patients with lung adenocarcinoma and the relationship between the osteosclerotic changes and the response to the therapy. Materials and methods: Our study included 41 patients with...

  • Advances in Supportive Care of Patients With Cancer and Bone Metastases:Nursing Implications of Zoledronic Acid. Maxwell, Cathy; Swift, Regina; Goode, Melissa; Doane, Lois; Rogers, Miriam // Clinical Journal of Oncology Nursing;Jul/Aug2003, Vol. 7 Issue 4, p403 

    The knowledge and training of nursing staff is essential for the safety and comfort of patients receiving IV therapies. The use of IV bisphosphonates as an adjunct to standard antineoplastic therapies in patients with advanced cancer is becoming widespread.Zoledronic acid and pamidronate ...

  • Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Oster, Gerry; Lamerato, Lois; Glass, Andrew G.; Richert-Boe, Kathryn E.; Lopez, Andrea; Chung, Karen; Richhariya, Akshara; Dodge, Tracy; Wolff, Greg G.; Balakumaran, Arun; Edelsberg, John // Supportive Care in Cancer;Dec2013, Vol. 21 Issue 12, p3279 

    Purpose: To document the risk of skeletal complications in patients with bone metastases from breast cancer (BC), lung cancer (LC), or prostate cancer (PC) in routine clinical practice. Methods: We used data from two large US health systems to identify patients aged ≥18 years with...

  • Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study. Piantedosi, F. V.; Caputo, F.; Mazzarella, G.; Gilli, M.; Pontillo, A.; D'Agostino, D.; Campbell, S.; Marsico, S. A.; Bianco, A. // Cancer Chemotherapy & Pharmacology;Apr2008, Vol. 61 Issue 5, p803 

    Although platinum-based two-drug combinations represent the elective therapeutic approach for advanced/metastatic NSCLC, there is still interest in exploring the efficacy and tolerability of platinum-free combinations including third generation agents in selected NSCLC population. Based on the...

  • An interesting tumour case: Seeding To Incision Scar, Osseous Metaplasia In Metastasis And More. Isken, Tonguc; Ozgentas, Ege; Gulkesen, Hakan; Bulut, Kemal; Karpuzuglu, Güten // Internet Journal of Urology;2008, Vol. 5 Issue 2, p15 

    We reported a tumour which has many different interesting characteristics. There was an ossified metastasis of bladder tumour to the abdominal wound 19 years after partial cystectomy. Also origin of the metastasis was direct seeding to the incision line. Additionally eight years after...

  • SECONDARY BONE TUMOURS -- OVERVIEW, INCIDENCE AND HISTOPATHOLOGY. Şişu, Alina Maria; Petrescu, Codruţa Ileana; Stana, Loredana Gabriela; Folescu, Roxana; Motoc, A. // Romanian Journal of Functional & Clinical, Macro- & Microscopica;2012, Vol. 11 Issue 4, p485 

    Cancer and osseous metastases are highlighted from The Iron Age, 10,000 years BC. From Hippocrates and Galien we have learnt about foetus malignant tumours and carcinoma. Then, 15 centuries later, Le Dran discovered metastases. In the 20 century term "virus-cancer" has been stated. In literature...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics